Ovid Therapeutics Announces Election of Bart Friedman to Its Board of Directors
New York, NY – November 23, 2016 – (Business Wire) – Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, today announced that Bart Friedman has joined the Company’s Board of Directors. Mr. Friedman is a senior partner at the Wall Street law firm Cahill Gordon & Reindel LLP and is Chairman of its Business Development Committee.
“We are delighted that Bart is joining our Board. Our goal is to build a world-leading neurology company with a Board of unparalleled and diverse capabilities. Bart’s broad experience, exceptional reputation, deep knowledge, and intellect are exactly what we require to achieve this goal,” said Dr. Jeremy Levin, Chief Executive Officer and Chairman of Ovid. “It is a privilege to have the opportunity to work with him as we seek to bring medicines to patients and help the families of those with these significant disorders.”
At Cahill Gordon & Reindel, Mr. Friedman advises leading financial institutions and global corporations, boards of directors, audit committees, and officers and directors of publicly held companies in significant corporate and securities matters, corporate compliance, and enforcement challenges. Mr. Friedman chairs the Board of Directors of the Sanford C. Bernstein Mutual Funds, is the Lead Independent Director of Allied World Assurance Holdings, serves on the Board of Trustees of The Brookings Institution and chairs its Audit Committee, and serves on the Board of Lincoln Center for the Performing Arts and chairs its Audit Committee. Mr. Friedman also serves on the Membership Committee of the Council on Foreign Relations. Earlier in his career, Mr. Friedman worked at the Securities and Exchange Commission as Special Counsel and later as Assistant Director. He earned his J.D. at Harvard Law School and was on the research faculty of Harvard Business School during and following his graduation from Harvard Law School and prior to joining Cahill.
Mr. Friedman commented, “I have been impressed with Ovid’s mission, strategy, and progress as it becomes a pre-eminent global, commercial company focused on orphan diseases of the brain. This is an important area of medical need, and Ovid is well-positioned to play a leading role. I am honored to serve on Ovid’s Board.”
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development, and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development. Ovid recently completed a substantially oversubscribed $75 Million Series B financing led by Fidelity Management and Research Company and including Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates (on behalf of certain clients), Redmile Group, DoubleLine Equity Healthcare fund, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.
For more information on Ovid, please visit http://ovidrx.com.
Burns McClellan, on behalf of Ovid Therapeutics
Justin Jackson, 212-213-0006, ext. 327